Tower Research Capital LLC TRC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 29.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,838 shares of the biotechnology company’s stock after buying an additional 416 shares during the period. Tower Research Capital LLC TRC’s holdings in United Therapeutics were worth $412,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in United Therapeutics by 5.5% in the 1st quarter. Bank of New York Mellon Corp now owns 610,153 shares of the biotechnology company’s stock valued at $136,650,000 after buying an additional 31,546 shares in the last quarter. California State Teachers Retirement System boosted its holdings in United Therapeutics by 24.1% in the 1st quarter. California State Teachers Retirement System now owns 71,591 shares of the biotechnology company’s stock valued at $16,034,000 after purchasing an additional 13,892 shares during the period. US Bancorp DE boosted its holdings in United Therapeutics by 31.9% in the 1st quarter. US Bancorp DE now owns 1,905 shares of the biotechnology company’s stock valued at $427,000 after purchasing an additional 461 shares during the period. Roundview Capital LLC boosted its holdings in United Therapeutics by 26.0% in the 1st quarter. Roundview Capital LLC now owns 2,376 shares of the biotechnology company’s stock valued at $532,000 after purchasing an additional 490 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in United Therapeutics in the 1st quarter valued at $492,000. 95.02% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $227.77, for a total transaction of $1,366,620.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,336,154.23. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Paul A. Mahon sold 2,500 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $243.87, for a total value of $609,675.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,925,398.13. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $227.77, for a total transaction of $1,366,620.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,336,154.23. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,500 shares of company stock valued at $5,939,595. Insiders own 12.50% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on UTHR
United Therapeutics Price Performance
UTHR stock opened at $231.06 on Wednesday. The stock has a market capitalization of $10.84 billion, a price-to-earnings ratio of 13.07 and a beta of 0.61. The firm’s 50-day moving average price is $231.09 and its two-hundred day moving average price is $229.11. The company has a current ratio of 8.68, a quick ratio of 8.40 and a debt-to-equity ratio of 0.15. United Therapeutics Co. has a 12-month low of $201.65 and a 12-month high of $283.09.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $5.24 EPS for the quarter, beating the consensus estimate of $4.57 by $0.67. The firm had revenue of $596.50 million during the quarter, compared to the consensus estimate of $524.18 million. United Therapeutics had a net margin of 41.29% and a return on equity of 17.52%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.41 earnings per share. As a group, equities analysts predict that United Therapeutics Co. will post 18.95 earnings per share for the current year.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Stories
- Five stocks we like better than United Therapeutics
- The “How” and “Why” of Investing in 5G Stocks
- 5 Best Fintech Banks to Invest in Now
- Investing in Travel Stocks Benefits
- 3 Smart AI ETFs For Intelligent Passive Investing Needs
- How to Start Investing in Real Estate
- 4 Reasons Zoom Video is Ready to Rock Into a Reversal
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
